Can Investors Expect Anything Good From Valeant Pharmaceuticals Intl Inc.?

While Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) won’t default, it needs to show that it can be profitable and pay down its debt.

The Motley Fool

It seems every week there is another problem with Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX). Bond holders are hinting that Valeant will default on its debt and wind up losing everything. It can be difficult to see through all the noise to determine whether or not Valeant will be able to turn things around and potentially reward investors.

So let’s stick to the facts.

A default was only going to take place if Valeant didn’t file its 10Q by July 18. It filed its 10Q on June 7, more than a month sooner than when management actually promised to have it for investors. There’s no denying that the company has $30 billion in debt, but it’s not going to default unless it stops making payments. All this talk about a default appears to be fear and uncertainty.

Yet there is one important thing to remember about the default: in the event of bankruptcy, common shareholders are the last to get anything. Those who lent money to Valeant receive money first, and often there’s nothing left for the average investor.

In that 10Q for the first quarter of 2016, things were a little chaotic. It had $2.4 billion in total revenue, which is actually up 9% from the restated first quarter of 2015. However, its GAAP EPS was actually a loss of $1.08. Yet its adjusted EPS (non-GAAP) was a positive $1.27. Further, its GAAP cash flow from operations was $558 million, up 14% year over year.

My primary concern is that its organic-based revenue–the money from products it already owns–was down $289 million. It’s only earning more revenue from new acquisitions.

Then there’s the updated full-year 2016 guidance. Management expects revenue to be in the range of $9.9-10.1 billion, which is down from an original expectation of $11-11.2 billion. Valeant expects that its adjusted EPS will be anywhere from $6.60 to $7.00, which is down from $8.50 to $9.50. So management expects the company to make less money.

What should investors do?

There are two things that matter most to me when it comes to Valeant.

The first is whether or not the company can be profitable when it can’t egregiously overcharge for drugs. Its business model had been to acquire a company or portfolio of drugs, make sure they crossed the regulatory finish line, and then hike the price. In some instances, the price hike was hundreds of percentage points. If it can be profitable without doing that, I’ll be confident.

The other thing it needs to show me is if it can actually get its debt under control. A debt load of $30 billion for a company like Valeant is far too much. Fortunately, it can sell some of its assets to pay down that debt. Sources tell the Financial Post that Valeant is considering selling its Amoun Pharmaceutical Co. division, which it acquired last year for US$800 million.

Valeant also has other non-core assets that it might sell, specifically some of its Latin American operations.

Finally, it’s believed that dermatological acquisition Obagi Medical Products Inc., the Provenge treatment, and some of the Marathon Pharmaceuticals drugs may also be sold.

For an investor who wants to pick up shares, right now is a very risky time. While I have faith in its experienced new CEO, Valeant is a big company that will take time to turn around. If it shows in future earnings that it is growing its organic revenue and actually making a profit, this company will become a buy. Further, if it starts to pay down debt, it could become a very attractive company. For now, research and wait for the right moment.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »